Biolaxy Secures IND Approval for Oral Insulin

Shanghai Biolaxy announced the Chinese State Food & Drug Administration has approved the investigational new drug application (IND) for its oral insulin project (Nodlin), an innovative insulin formulation to treat diabetes.
San Francisco Business Journal